216 related articles for article (PubMed ID: 31009286)
1. External Validation of the Prostate Cancer Specific Comorbidity Index: A Claims Based Tool for the Prediction of Life Expectancy in Men with Prostate Cancer.
Daskivich TJ; Thomas IC; Luu M; Shelton JB; Makarov DV; Skolarus TA; Leppert JT
J Urol; 2019 Sep; 202(3):518-524. PubMed ID: 31009286
[TBL] [Abstract][Full Text] [Related]
2. An Age Adjusted Comorbidity Index to Predict Long-Term, Other Cause Mortality in Men with Prostate Cancer.
Daskivich TJ; Kwan L; Dash A; Saigal C; Litwin MS
J Urol; 2015 Jul; 194(1):73-8. PubMed ID: 25623745
[TBL] [Abstract][Full Text] [Related]
3. Using an Automated Electronic Health Record Score To Estimate Life Expectancy In Men Diagnosed With Prostate Cancer In The Veterans Health Administration.
Soerensen SJC; Thomas IC; Schmidt B; Daskivich TJ; Skolarus TA; Jackson C; Osborne TF; Chertow GM; Brooks JD; Rehkopf DH; Leppert JT
Urology; 2021 Sep; 155():70-76. PubMed ID: 34139251
[TBL] [Abstract][Full Text] [Related]
4. Validation of the prostate cancer comorbidity index in predicting cause-specific mortality in men undergoing radical prostatectomy.
Chen MS; Howard LE; Stock S; Dolgner A; Freedland SJ; Aronson W; Terris M; Klaassen Z; Kane C; Amling C; Cooperberg M; Daskivich TJ
Prostate Cancer Prostatic Dis; 2023 Dec; 26(4):715-721. PubMed ID: 35668181
[TBL] [Abstract][Full Text] [Related]
5. Life expectancy estimates for patients diagnosed with prostate cancer in the Veterans Health Administration.
Sohlberg EM; Thomas IC; Yang J; Kapphahn K; Daskivich TJ; Skolarus TA; Shelton JB; Makarov DV; Bergman J; Bang CK; Goldstein MK; Wagner TH; Brooks JD; Desai M; Leppert JT
Urol Oncol; 2020 Sep; 38(9):734.e1-734.e10. PubMed ID: 32674954
[TBL] [Abstract][Full Text] [Related]
6. Improved prediction of long-term, other cause mortality in men with prostate cancer.
Daskivich TJ; Chamie K; Kwan L; Labo J; Dash A; Greenfield S; Litwin MS
J Urol; 2011 Nov; 186(5):1868-73. PubMed ID: 21944092
[TBL] [Abstract][Full Text] [Related]
7. Long-term survival among men with conservatively treated localized prostate cancer.
Albertsen PC; Fryback DG; Storer BE; Kolon TF; Fine J
JAMA; 1995 Aug 23-30; 274(8):626-31. PubMed ID: 7637143
[TBL] [Abstract][Full Text] [Related]
8. Undertreatment of Men in Their Seventies with High-risk Nonmetastatic Prostate Cancer.
Bratt O; Folkvaljon Y; Hjälm Eriksson M; Akre O; Carlsson S; Drevin L; Franck Lissbrant I; Makarov D; Loeb S; Stattin P
Eur Urol; 2015 Jul; 68(1):53-8. PubMed ID: 25813688
[TBL] [Abstract][Full Text] [Related]
9. Successful external validation of a model to predict other cause mortality in localized prostate cancer.
Kent M; Penson DF; Albertsen PC; Goodman M; Hamilton AS; Stanford JL; Stroup AM; Ehdaie B; Scardino PT; Vickers AJ
BMC Med; 2016 Feb; 14():25. PubMed ID: 26860993
[TBL] [Abstract][Full Text] [Related]
10. The impact of life expectancy on cost-effectiveness of treatment options for clinically localized prostate cancer.
Naser-Tavakolian A; Venkataramana A; Spiegel B; Almario C; Kokorowski P; Freedland SJ; Anger JT; Leppert JT; Daskivich TJ
Urol Oncol; 2023 Apr; 41(4):205.e1-205.e10. PubMed ID: 36737259
[TBL] [Abstract][Full Text] [Related]
11. Variation in treatment associated with life expectancy in a population-based cohort of men with early-stage prostate cancer.
Daskivich TJ; Lai J; Dick AW; Setodji CM; Hanley JM; Litwin MS; Saigal C;
Cancer; 2014 Dec; 120(23):3642-50. PubMed ID: 25042117
[TBL] [Abstract][Full Text] [Related]
12. Time Trends in Use of Radical Prostatectomy by Tumor Risk and Life Expectancy in a National Veterans Affairs Cohort.
Vaculik K; Luu M; Howard LE; Aronson W; Terris M; Kane C; Amling C; Cooperberg M; Freedland SJ; Daskivich TJ
JAMA Netw Open; 2021 Jun; 4(6):e2112214. PubMed ID: 34081138
[TBL] [Abstract][Full Text] [Related]
13. Weighted versus unweighted Charlson score to predict long-term other-cause mortality in men with early-stage prostate cancer.
Daskivich TJ; Kwan L; Dash A; Greenfield S; Litwin MS
Eur Urol; 2014 Dec; 66(6):1002-9. PubMed ID: 24924554
[TBL] [Abstract][Full Text] [Related]
14. Spanish validation of Charlson index applied to prostate cancer.
Casas Duran F; Valduvieco I; Oses G; Cortés KS; Barreto TD; Muñoz-Guglielmetti D; Ferrer F
Clin Transl Oncol; 2020 Jul; 22(7):1187-1192. PubMed ID: 31748962
[TBL] [Abstract][Full Text] [Related]
15. Validation of an Age-adjusted Prostate Cancer-Specific Comorbidity Index.
Froehner M; Koch R; Hübler M; Wirth MP
Eur Urol; 2016 May; 69(5):764-6. PubMed ID: 26558839
[TBL] [Abstract][Full Text] [Related]
16. National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making.
Drazer MW; Prasad SM; Huo D; Schonberg MA; Dale W; Szmulewitz RZ; Eggener SE
Cancer; 2014 May; 120(10):1491-8. PubMed ID: 24523016
[TBL] [Abstract][Full Text] [Related]
17. Re: External Validation of the Prostate Cancer Specific Comorbidity Index: A Claims Based Tool for the Prediction of Life Expectancy in Men with Prostate Cancer.
Froehner M; Koch R; Thomas C
J Urol; 2020 Feb; 203(2):420. PubMed ID: 31596669
[No Abstract] [Full Text] [Related]
18. Predicting Life Expectancy in Men Diagnosed with Prostate Cancer.
Sammon JD; Abdollah F; D'Amico A; Gettman M; Haese A; Suardi N; Vickers A; Trinh QD
Eur Urol; 2015 Nov; 68(5):756-65. PubMed ID: 25819724
[TBL] [Abstract][Full Text] [Related]
19. Individual prognosis at diagnosis in nonmetastatic prostate cancer: Development and external validation of the PREDICT Prostate multivariable model.
Thurtle DR; Greenberg DC; Lee LS; Huang HH; Pharoah PD; Gnanapragasam VJ
PLoS Med; 2019 Mar; 16(3):e1002758. PubMed ID: 30860997
[TBL] [Abstract][Full Text] [Related]
20. Claims-Based Approach to Predict Cause-Specific Survival in Men With Prostate Cancer.
Riviere P; Tokeshi C; Hou J; Nalawade V; Sarkar R; Paravati AJ; Schiaffino M; Rose B; Xu R; Murphy JD
JCO Clin Cancer Inform; 2019 Mar; 3():1-7. PubMed ID: 30830794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
